INFLUENCE OF LOCAL APPLICATION OF POLYOXIDONIUM ON SYMPTOMS AND COURSE OF ACUTE RESPIRATORY VIRAL INFECTION IN CHILDREN: RESULTS OF MULTICENTER DOUBLE-BLIND PLACEBO CONTROLLED STUDY

Aim. To confirm advantages of Polyoxidonium® local application therapeutic effect in comparison with placebo when being used as a part of complex therapy in children aged 1 to 12 years diagnosed with acute respiratory viral infection (ARVI). Materials and methods. The study included 155 children aged 1 to 12 years diagnosed with ARVI. The study group included 76 children in whom complex therapy included Polyoxidonium® and comparison group included 79 children who received placebo as a part of complex therapy. The study outcome measures evaluating therapy effectiveness included intoxication symptoms, nasal mucosa inflammation dynamics, total sum of the symptoms points at the 3rd, 5th, and 8th days of treatment, and the duration of fever. Results. According to study results the advantage of Polyoxidonium® use in comparison with placebo in complex treatment of children aged 1 to 12 years diagnosed with ARVI was established. Inclusion of Polyoxidonium in complex ARVI treatment in children allows to provide better control of intoxication symptoms to decrease severity of symptoms such as “nasal discharge” and “nasal blockage” by the 5th day of treatment, to double the amount of patients without the “nasal discharge” symptom by the 3rd and 5th days of treatment, and to decrease the severity of infection inflammatory process. Conclusion. Local application of Polyoxidonium® in complex treatment of ARVI in children aged 1 to 12 years showed clinical effectiveness and safety.

children, acute respiratory viral infection, Polyoxidonium, clinical study